A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria

被引：0
|
作者：
Bernd Hoppe
Patrick Niaudet
Rémi Salomon
Jérôme Harambat
Sally-Anne Hulton
William Van’t Hoff
Shabbir H. Moochhala
Georges Deschênes
Elisabeth Lindner
Anna Sjögren
Pierre Cochat
机构：
[1] University Hospital Bonn,Department of Pediatrics, Division of Pediatric Nephrology
[2] Université Paris-Descartes,Pediatric Nephrology, Necker Hospital
[3] Centre Hospitalier Universitaire de Bordeaux,Centre de référence Maladies Rénales Rares du Sud
[4] Birmingham Children’s Hospital NHS Foundation Trust,Ouest
[5] Great Ormond Street Hospital,Department of Paediatric Nephrology
[6] Royal Free Campus and Hospital,Renal Unit
[7] Robert Debré Hospital,UCL Centre for Nephrology
[8] OxThera AB,Pediatric Nephrology Department
[9] Hôpital Femme Mère Enfant,Centre de référence des Maladies Rénales Rares
来源：
Pediatric Nephrology | 2017年 / 32卷
关键词：
Primary hyperoxaluria; Oxalate; Kidney; Kidney function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：781 / 790
页数：9
相关论文
共 50 条
  • [31] A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults
    Huang, Hao
    FRONTIERS IN AGING, 2022, 3
  • [32] Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
    Castellano, Daniel E.
    Duran, Ignacio
    Mellado, Begona
    Climent Duran, Miguel Angel A.
    Garcia del Muro, Xavier
    Sala Gonzalez, Nuria
    Alonso Gordoa, Teresa
    Sevillano, Elena
    Domenech, Montserrat
    Paramio, Jesus
    Real, Francisco X.
    Malats, Nuria
    Luis Sanz, Juan
    Font, Albert
    Cris, Fundacion
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [33] Orally Administered Manganese With and Without Ascorbic Acid as a Liver-Specific Contrast Agent and Bowel Marker for Magnetic Resonance Imaging Phase I Clinical Trial Assessing Efficacy and Safety
    Leander, Peter
    Golman, Klaes
    Mansson, Sven
    Hoglund, Peter
    INVESTIGATIVE RADIOLOGY, 2010, 45 (09) : 559 - 564
  • [34] Primary Results on Safety and Efficacy From the LEADLESS II-Phase 2 Worldwide Clinical Trial
    Reddy, Vivek Y.
    Exner, Derek V.
    Doshi, Rahul
    Tomassoni, Gery
    Bunch, T. Jared
    Estes, N. A. Mark
    Neuz, Petr
    Paulin, Frederic L.
    Guerrero, Juan Jose Garcia
    Cantillon, Daniel J.
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2022, 8 (01) : 115 - 117
  • [35] Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial (vol 19, pg 727, 2020)
    Goadsby, P. J.
    Dodick, D. W.
    Ailani, J.
    LANCET NEUROLOGY, 2020, 19 (11): : E10 - E10
  • [36] A Phase II, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone in Japanese Patients With Recurrent Malignant Glioma
    Matsutani, M.
    Nishikawa, R.
    Kobayashi, H.
    Takano, S.
    Shinoura, N.
    Nagane, M.
    Narita, Y.
    Aokis, T.
    Sugiyama, K.
    Kuratsu, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S575 - S575
  • [37] Randomised clinical trial: A double-blind, randomised, active-controlled, phase 3 study to evaluate the safety and efficacy of Tegoprazan in patients with gastric ulcer
    Choe, YoungHee
    Cho, YuKyung
    Lim, ChulHyun
    Choi, Myung-Gyu
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32
  • [38] Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease
    Froelich, Lutz
    Wunderlich, Glen
    Thamer, Claus
    Roehrle, Michael
    Garcia, Miguel, Jr.
    Dubois, Bruno
    ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (1)
  • [39] Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors
    Awada, A.
    Hendlisz, A.
    Whenham, N.
    Gil, T.
    Christensen, O.
    Lathia, C.
    Bartholomeus, S.
    Delabaye, I.
    De Valeriola, D.
    Brendel, E.
    Delaunoit, T.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
  • [40] Primary Analysis of a Randomized Phase II Study to Evaluate the Efficacy and Safety of Evobrutinib, a BTK Inhibitor, in Patients with Relapsing MS
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin
    Staikov, Ivan
    Piasecka-Strycznska, Karolina
    Willmer, Jonathan
    Martin, Emily
    Dangond, Fernando
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 52 - 53
12345